Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16062052 | 0.85 | BACE1 (0.34) | BACE1 | |
| SCHEMBL29704025 | 0.84 | TKT (0.36) | BACE1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15940613 | 0.79 | PDCD1LG2 (0.34) | PDCD1LG2CD274 | |
| SCHEMBL17433803 | 0.77 | BACE1 (0.36) | BACE1 | |
| SCHEMBL18981834 | 0.75 | — | — | |
| SCHEMBL2063296 | 0.75 | FAAH (0.40) | BACE1 | |
| SCHEMBL20501232 | 0.75 | CA12 (0.33) | BACE1 | |
| SCHEMBL1243491 | 0.75 | MEN1 (0.32) | BACE1 | |
| SCHEMBL5313454 | 0.75 | CYP3A4 (0.40) | BACE1PDCD1LG2CD274 | |
| SCHEMBL15595871 | 0.74 | TUBB4A (0.51) | PDCD1LG2CD274TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| EP-1915373-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | Merck and Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | BACE1 1060/4885PDCD1LG2 1757/4885CD274 1226/4885 |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPK7 | BACE1 1134/4885PDCD1LG2 1766/4885CD274 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.